Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent Shigella flexneri.

McCloskey MC, Shaheen S, Rabago L, Hulverson MA, Choi R, Barrett LK, Arnold SLM.

Sci Rep. 2019 Sep 19;9(1):13567. doi: 10.1038/s41598-019-49729-2.

2.

P-Glycoprotein-Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium.

Arnold SLM, Choi R, Hulverson MA, Whitman GR, Mccloskey MC, Dorr CS, Vidadala RSR, Khatod M, Morada M, Barrett LK, Maly DJ, Yarlett N, Van Voorhis WC.

J Infect Dis. 2019 Aug 30;220(7):1188-1198. doi: 10.1093/infdis/jiz269.

3.

Extreme angle, tip-tilt MEMS micromirror enabling full hemispheric, quasi-static optical coverage.

Pollock C, Javor J, Stange A, Barrett LK, Bishop DJ.

Opt Express. 2019 May 27;27(11):15318-15326. doi: 10.1364/OE.27.015318.

PMID:
31163729
4.

Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy.

Sánchez-Sánchez R, Ferre I, Re M, Ramos JJ, Regidor-Cerrillo J, Pizarro Díaz M, González-Huecas M, Tabanera E, Benavides J, Hemphill A, Hulverson MA, Barrett LK, Choi R, Whitman GR, Ojo KK, Van Voorhis WC, Ortega-Mora LM.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e02527-18. doi: 10.1128/AAC.02527-18. Print 2019 Jul.

PMID:
31061151
5.

Building a Casimir metrology platform with a commercial MEMS sensor.

Stange A, Imboden M, Javor J, Barrett LK, Bishop DJ.

Microsyst Nanoeng. 2019 Apr 22;5:14. doi: 10.1038/s41378-019-0054-5. eCollection 2019.

6.

Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro.

Shrestha A, Ojo KK, Koston F, Ruttkowski B, Vidadala RSR, Dorr CS, Navaluna ED, Whitman GR, Barrett KF, Barrett LK, Hulverson MA, Choi R, Michaels SA, Maly DJ, Hemphill A, Van Voorhis WC, Joachim A.

Int J Parasitol Drugs Drug Resist. 2019 Aug;10:9-19. doi: 10.1016/j.ijpddr.2019.03.004. Epub 2019 Apr 2.

7.

Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Huang W, Hulverson MA, Choi R, Arnold SLM, Zhang Z, McCloskey MC, Whitman GR, Hackman RC, Rivas KL, Barrett LK, Ojo KK, Van Voorhis WC, Fan E.

J Med Chem. 2019 Mar 28;62(6):3135-3146. doi: 10.1021/acs.jmedchem.9b00069. Epub 2019 Mar 15.

PMID:
30830766
8.

Oral versus Intravenous Antibiotics for Bone and Joint Infection.

Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, Lipsky BA, Hughes HC, Bose D, Kümin M, Scarborough C, Matthews PC, Brent AJ, Lomas J, Gundle R, Rogers M, Taylor A, Angus B, Byren I, Berendt AR, Warren S, Fitzgerald FE, Mack DJF, Hopkins S, Folb J, Reynolds HE, Moore E, Marshall J, Jenkins N, Moran CE, Woodhouse AF, Stafford S, Seaton RA, Vallance C, Hemsley CJ, Bisnauthsing K, Sandoe JAT, Aggarwal I, Ellis SC, Bunn DJ, Sutherland RK, Barlow G, Cooper C, Geue C, McMeekin N, Briggs AH, Sendi P, Khatamzas E, Wangrangsimakul T, Wong THN, Barrett LK, Alvand A, Old CF, Bostock J, Paul J, Cooke G, Thwaites GE, Bejon P, Scarborough M; OVIVA Trial Collaborators.

N Engl J Med. 2019 Jan 31;380(5):425-436. doi: 10.1056/NEJMoa1710926.

9.

Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.

Hulverson MA, Bruzual I, McConnell EV, Huang W, Vidadala RSR, Choi R, Arnold SLM, Whitman GR, McCloskey MC, Barrett LK, Rivas KL, Scheele S, DeRocher AE, Parsons M, Ojo KK, Maly DJ, Fan E, Van Voorhis WC, Doggett JS.

J Infect Dis. 2019 Apr 16;219(9):1464-1473. doi: 10.1093/infdis/jiy664.

PMID:
30423128
10.

Screening of the Pathogen Box for inhibitors with dual efficacy against Giardia lamblia and Cryptosporidium parvum.

Hennessey KM, Rogiers IC, Shih HW, Hulverson MA, Choi R, McCloskey MC, Whitman GR, Barrett LK, Merritt EA, Paredez AR, Ojo KK.

PLoS Negl Trop Dis. 2018 Aug 6;12(8):e0006673. doi: 10.1371/journal.pntd.0006673. eCollection 2018 Aug.

11.

Tunable Infrared Metasurface on a Soft Polymer Scaffold.

Reeves JB, Jayne RK, Stark TJ, Barrett LK, White AE, Bishop DJ.

Nano Lett. 2018 May 9;18(5):2802-2806. doi: 10.1021/acs.nanolett.7b05042. Epub 2018 Apr 23.

PMID:
29683680
12.

Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.

Scheele S, Geiger JA, DeRocher AE, Choi R, Smith TR, Hulverson MA, Vidadala RSR, Barrett LK, Maly DJ, Merritt EA, Ojo KK, Van Voorhis WC, Parsons M.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00051-18. doi: 10.1128/AAC.00051-18. Print 2018 Jun.

13.

7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.

Vidadala RSR, Golkowski M, Hulverson MA, Choi R, McCloskey MC, Whitman GR, Huang W, Arnold SLM, Barrett LK, Fan E, Merritt EA, Van Voorhis WC, Ojo KK, Maly DJ.

ACS Infect Dis. 2018 Apr 13;4(4):516-522. doi: 10.1021/acsinfecdis.7b00224. Epub 2018 Mar 16.

14.

Safety and efficacy of the bumped kinase inhibitor BKI-1553 in pregnant sheep experimentally infected with Neospora caninum tachyzoites.

Sánchez-Sánchez R, Ferre I, Re M, Vázquez P, Ferrer LM, Blanco-Murcia J, Regidor-Cerrillo J, Pizarro Díaz M, González-Huecas M, Tabanera E, García-Lunar P, Benavides J, Castaño P, Hemphill A, Hulverson MA, Whitman GR, Rivas KL, Choi R, Ojo KK, Barrett LK, Van Voorhis WC, Ortega-Mora LM.

Int J Parasitol Drugs Drug Resist. 2018 Apr;8(1):112-124. doi: 10.1016/j.ijpddr.2018.02.003. Epub 2018 Mar 2.

15.

Translational evidence for two distinct patterns of neuroaxonal injury in sepsis: a longitudinal, prospective translational study.

Ehler J, Barrett LK, Taylor V, Groves M, Scaravilli F, Wittstock M, Kolbaske S, Grossmann A, Henschel J, Gloger M, Sharshar T, Chretien F, Gray F, Nöldge-Schomburg G, Singer M, Sauer M, Petzold A.

Crit Care. 2017 Oct 23;21(1):262. doi: 10.1186/s13054-017-1850-7.

16.

Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis.

Hulverson MA, Choi R, Arnold SLM, Schaefer DA, Hemphill A, McCloskey MC, Betzer DP, Müller J, Vidadala RSR, Whitman GR, Rivas KL, Barrett LK, Hackman RC, Love MS, McNamara CW, Shaughnessy TK, Kondratiuk A, Kurnick M, Banfor PN, Lynch JJ, Freiberg GM, Kempf DJ, Maly DJ, Riggs MW, Ojo KK, Van Voorhis WC.

Int J Parasitol. 2017 Oct;47(12):753-763. doi: 10.1016/j.ijpara.2017.08.006. Epub 2017 Sep 9.

17.

Recombinant human G6PD for quality control and quality assurance of novel point-of-care diagnostics for G6PD deficiency.

Kahn M, LaRue N, Zhu C, Pal S, Mo JS, Barrett LK, Hewitt SN, Dumais M, Hemmington S, Walker A, Joynson J, Leader BT, Van Voorhis WC, Domingo GJ.

PLoS One. 2017 May 26;12(5):e0177885. doi: 10.1371/journal.pone.0177885. eCollection 2017.

18.

Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection.

Arnold SLM, Choi R, Hulverson MA, Schaefer DA, Vinayak S, Vidadala RSR, McCloskey MC, Whitman GR, Huang W, Barrett LK, Ojo KK, Fan E, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC.

J Infect Dis. 2017 Jul 1;216(1):55-63. doi: 10.1093/infdis/jix247.

19.

5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum.

Huang W, Choi R, Hulverson MA, Zhang Z, McCloskey MC, Schaefer DA, Whitman GR, Barrett LK, Vidadala RSR, Riggs MW, Maly DJ, Van Voorhis WC, Ojo KK, Fan E.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00020-17. doi: 10.1128/AAC.00020-17. Print 2017 Aug.

20.

Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis.

Müller J, Aguado-Martínez A, Ortega-Mora LM, Moreno-Gonzalo J, Ferre I, Hulverson MA, Choi R, McCloskey MC, Barrett LK, Maly DJ, Ojo KK, Van Voorhis W, Hemphill A.

J Antimicrob Chemother. 2017 Aug 1;72(8):2334-2341. doi: 10.1093/jac/dkx134.

21.

Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy.

Hulverson MA, Vinayak S, Choi R, Schaefer DA, Castellanos-Gonzalez A, Vidadala RSR, Brooks CF, Herbert GT, Betzer DP, Whitman GR, Sparks HN, Arnold SLM, Rivas KL, Barrett LK, White AC Jr, Maly DJ, Riggs MW, Striepen B, Van Voorhis WC, Ojo KK.

J Infect Dis. 2017 Apr 15;215(8):1275-1284. doi: 10.1093/infdis/jix120. Erratum in: J Infect Dis. 2018 Jan 4;217(2):340.

22.

Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Schaefer DA, Betzer DP, Smith KD, Millman ZG, Michalski HC, Menchaca SE, Zambriski JA, Ojo KK, Hulverson MA, Arnold SL, Rivas KL, Vidadala RS, Huang W, Barrett LK, Maly DJ, Fan E, Van Voorhis WC, Riggs MW.

J Infect Dis. 2016 Dec 15;214(12):1856-1864. Epub 2016 Oct 17.

23.

Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase.

Hewitt SN, Dranow DM, Horst BG, Abendroth JA, Forte B, Hallyburton I, Jansen C, Baragaña B, Choi R, Rivas KL, Hulverson MA, Dumais M, Edwards TE, Lorimer DD, Fairlamb AH, Gray DW, Read KD, Lehane AM, Kirk K, Myler PJ, Wernimont A, Walpole C, Stacy R, Barrett LK, Gilbert IH, Van Voorhis WC.

ACS Infect Dis. 2017 Jan 13;3(1):34-44. doi: 10.1021/acsinfecdis.6b00078. Epub 2016 Nov 16.

24.

A Novel Calcium-Dependent Kinase Inhibitor, Bumped Kinase Inhibitor 1517, Cures Cryptosporidiosis in Immunosuppressed Mice.

Castellanos-Gonzalez A, Sparks H, Nava S, Huang W, Zhang Z, Rivas K, Hulverson MA, Barrett LK, Ojo KK, Fan E, Van Voorhis WC, White AC Jr.

J Infect Dis. 2016 Dec 15;214(12):1850-1855. Epub 2016 Oct 12.

25.

Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.

Ojo KK, Dangoudoubiyam S, Verma SK, Scheele S, DeRocher AE, Yeargan M, Choi R, Smith TR, Rivas KL, Hulverson MA, Barrett LK, Fan E, Maly DJ, Parsons M, Dubey JP, Howe DK, Van Voorhis WC.

Int J Parasitol. 2016 Dec;46(13-14):871-880. doi: 10.1016/j.ijpara.2016.08.003. Epub 2016 Oct 8.

26.

Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.

Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, Jones N.

BMC Infect Dis. 2016 Oct 11;16(1):556.

27.

Correction: Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis.

Ojo KK, Ranade RM, Zhang Z, Dranow DM, Myers JB, Choi R, Nakazawa Hewitt S, Edwards TE, Davies DR, Lorimer D, Boyle SM, Barrett LK, Buckner FS, Fan E, Van Voorhis WC.

PLoS One. 2016 Sep 22;11(9):e0163641. doi: 10.1371/journal.pone.0163641. eCollection 2016.

28.

Brucella melitensis Methionyl-tRNA-Synthetase (MetRS), a Potential Drug Target for Brucellosis.

Ojo KK, Ranade RM, Zhang Z, Dranow DM, Myers JB, Choi R, Nakazawa Hewitt S, Edwards TE, Davies DR, Lorimer D, Boyle SM, Barrett LK, Buckner FS, Fan E, Van Voorhis WC.

PLoS One. 2016 Aug 8;11(8):e0160350. doi: 10.1371/journal.pone.0160350. eCollection 2016. Erratum in: PLoS One. 2016;11(9):e0163641.

29.

Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.

Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ.

J Med Chem. 2016 Jul 14;59(13):6531-46. doi: 10.1021/acs.jmedchem.6b00760. Epub 2016 Jul 1.

30.

Mycobacterium Cytidylate Kinase Appears to Be an Undruggable Target.

Craig JK, Risler JK, Loesch KA, Dong W, Baker D, Barrett LK, Subramanian S, Samudrala R, Van Voorhis WC.

J Biomol Screen. 2016 Aug;21(7):695-700. doi: 10.1177/1087057116646702. Epub 2016 May 4.

PMID:
27146385
31.

Large-Area Growth of Turbostratic Graphene on Ni(111) via Physical Vapor Deposition.

Garlow JA, Barrett LK, Wu L, Kisslinger K, Zhu Y, Pulecio JF.

Sci Rep. 2016 Jan 29;6:19804. doi: 10.1038/srep19804.

32.

Bumped kinase inhibitor prohibits egression in Babesia bovis.

Pedroni MJ, Vidadala RS, Choi R, Keyloun KR, Reid MC, Murphy RC, Barrett LK, Van Voorhis WC, Maly DJ, Ojo KK, Lau AO.

Vet Parasitol. 2016 Jan 15;215:22-8. doi: 10.1016/j.vetpar.2015.10.023. Epub 2015 Nov 5.

33.

SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1.

Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RS, Scheele S, DeRocher AE, Choi R, Hulverson MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, Doggett JS, Van Voorhis WC, Fan E.

ACS Med Chem Lett. 2015 Oct 22;6(12):1184-1189. eCollection 2015 Dec 10.

34.

Increasing the structural coverage of tuberculosis drug targets.

Baugh L, Phan I, Begley DW, Clifton MC, Armour B, Dranow DM, Taylor BM, Muruthi MM, Abendroth J, Fairman JW, Fox D 3rd, Dieterich SH, Staker BL, Gardberg AS, Choi R, Hewitt SN, Napuli AJ, Myers J, Barrett LK, Zhang Y, Ferrell M, Mundt E, Thompkins K, Tran N, Lyons-Abbott S, Abramov A, Sekar A, Serbzhinskiy D, Lorimer D, Buchko GW, Stacy R, Stewart LJ, Edwards TE, Van Voorhis WC, Myler PJ.

Tuberculosis (Edinb). 2015 Mar;95(2):142-8. doi: 10.1016/j.tube.2014.12.003. Epub 2014 Dec 19.

35.

The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.

Keyloun KR, Reid MC, Choi R, Song Y, Fox AMW, Hillesland HK, Zhang Z, Vidadala R, Merritt EA, Lau AOT, Maly DJ, Fan E, Barrett LK, Van Voorhis WC, Ojo KK.

Parasitology. 2014 Sep;141(11):1499-1509. doi: 10.1017/S0031182014000857. Epub 2014 Jun 13.

36.

Urosepsis after transrectal ultrasonography-guided prostate biopsy: reaudit following a shortened antibiotic prophylaxis regimen.

Barrett LK, Hadway P, Waghorn DJ.

J Antimicrob Chemother. 2013 Dec;68(12):2959-60. doi: 10.1093/jac/dkt277. Epub 2013 Jul 3. No abstract available.

PMID:
23825382
37.

Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli.

Williamson DA, Barrett LK, Rogers BA, Freeman JT, Hadway P, Paterson DL.

Clin Infect Dis. 2013 Jul;57(2):267-74. doi: 10.1093/cid/cit193. Epub 2013 Mar 26. Review.

PMID:
23532481
38.

Stabilizing additives added during cell lysis aid in the solubilization of recombinant proteins.

Leibly DJ, Nguyen TN, Kao LT, Hewitt SN, Barrett LK, Van Voorhis WC.

PLoS One. 2012;7(12):e52482. doi: 10.1371/journal.pone.0052482. Epub 2012 Dec 20.

39.

Structure of thymidylate kinase from Ehrlichia chaffeensis.

Leibly DJ, Abendroth J, Bryan CM, Sankaran B, Kelley A, Barrett LK, Stewart L, Van Voorhis WC.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011 Sep 1;67(Pt 9):1090-4. doi: 10.1107/S174430911101493X. Epub 2011 Aug 16.

40.

Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy.

Hadway P, Barrett LK, Waghorn DJ, Hasan K, Bdesha A, Haldar N, Kelleher J.

BJU Int. 2009 Dec;104(11):1556-8. doi: 10.1111/j.1464-410X.2009.08959.x. No abstract available.

41.

Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis.

Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M.

Crit Care Med. 2007 Oct;35(10):2337-43.

PMID:
17944022
42.

Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase.

Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Hornéy C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CL, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH.

Antimicrob Agents Chemother. 2007 Oct;51(10):3659-71. Epub 2007 Jul 2.

43.

Vasopressin: mechanisms of action on the vasculature in health and in septic shock.

Barrett LK, Singer M, Clapp LH.

Crit Care Med. 2007 Jan;35(1):33-40. Review.

PMID:
17133186
44.

Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.

Eastman RT, Barrett LK, Dupuis K, Buckner FS, Van Voorhis WC.

Transfusion. 2005 Sep;45(9):1459-63.

PMID:
16131378
45.

Subfamily I Treponema pallidum repeat protein family: sequence variation and immunity.

Sun ES, Molini BJ, Barrett LK, Centurion-Lara A, Lukehart SA, Van Voorhis WC.

Microbes Infect. 2004 Jul;6(8):725-37.

PMID:
15207819
46.
47.

Serodiagnosis of syphilis: antibodies to recombinant Tp0453, Tp92, and Gpd proteins are sensitive and specific indicators of infection by Treponema pallidum.

Van Voorhis WC, Barrett LK, Lukehart SA, Schmidt B, Schriefer M, Cameron CE.

J Clin Microbiol. 2003 Aug;41(8):3668-74.

48.

Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV.

Van Voorhis WC, Barrett LK, Eastman RT, Alfonso R, Dupuis K.

Antimicrob Agents Chemother. 2003 Feb;47(2):475-9.

49.

Multiple alleles of Treponema pallidum repeat gene D in Treponema pallidum isolates.

Centurion-Lara A, Sun ES, Barrett LK, Castro C, Lukehart SA, Van Voorhis WC.

J Bacteriol. 2000 Apr;182(8):2332-5.

50.

Supplemental Content

Loading ...
Support Center